Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,515,102
  • Shares Outstanding, K 95,590
  • Annual Sales, $ 0 K
  • Annual Income, $ -92,060 K
  • 36-Month Beta 2.72
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.34
  • Number of Estimates 6
  • High Estimate -0.30
  • Low Estimate -0.36
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +2.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.95 +15.06%
on 07/30/18
17.50 -14.86%
on 08/16/18
+0.45 (+3.11%)
since 07/17/18
3-Month
12.20 +22.13%
on 06/11/18
17.50 -14.86%
on 08/16/18
-1.45 (-8.87%)
since 05/17/18
52-Week
4.55 +227.47%
on 08/22/17
19.90 -25.13%
on 03/13/18
+10.25 (+220.43%)
since 08/17/17

Most Recent Stories

More News
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its second quarter...

IOVA : 14.90 (-5.99%)
Iovance Biotherapeutics Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Iovance Biotherapeutics Inc (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time....

IOVA : 14.90 (-5.99%)
Iovance Biotherapeutics to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report...

IOVA : 14.90 (-5.99%)
A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?

Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist...

IOVA : 14.90 (-5.99%)
ORGS : 6.82 (-0.58%)
ARNA : 35.74 (-0.56%)
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar

Stock Research Monitor: JAGX, JAZZ, and LJPC

IOVA : 14.90 (-5.99%)
JAZZ : 173.81 (+0.40%)
Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%

Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

IOVA : 14.90 (-5.99%)
ILMN : 325.88 (-0.34%)
Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, today announced that the first patient...

IOVA : 14.90 (-5.99%)
Advaxis Appoints Molly Henderson as Chief Financial Officer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment...

ADXS : 1.44 (unch)
IOVA : 14.90 (-5.99%)
LBIO : 6.95 (-2.80%)
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

IOVA : 14.90 (-5.99%)
Iovance Biotherapeutics to Present at Two Investor Conferences in June

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 14.90 (-5.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade IOVA with:

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 16.30
1st Resistance Point 15.60
Last Price 14.90
1st Support Level 14.45
2nd Support Level 14.00

See More

52-Week High 19.90
Last Price 14.90
Fibonacci 61.8% 14.04
Fibonacci 50% 12.23
Fibonacci 38.2% 10.41
52-Week Low 4.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar